Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Filgotinib in Combination With Methotrexate in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate

ClinicalTrials.gov ID: NCT02889796

Public ClinicalTrials.gov record NCT02889796. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 3, 2026, 3:55 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-blind, Placebo- and Active-controlled, Multicenter, Phase 3 Study to Assess the Efficacy and Safety of Filgotinib Administered for 52 Weeks in Combination With Methotrexate to Subjects With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The primary objective of this study is to evaluate the effects of filgotinib versus placebo for the treatment of signs and symptoms of rheumatoid arthritis (RA) as measured by the percentage of participants achieving an American College of Rheumatology 20% improvement response (ACR20) at Week 12.

Study identification

NCT ID
NCT02889796
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Gilead Sciences
Industry
Enrollment
1,759 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Aug 29, 2016
Primary completion
Jul 3, 2018
Completion
Jun 19, 2019
Last update posted
Jun 8, 2021

2016 – 2019

United States locations

U.S. sites
48
U.S. states
18
U.S. cities
48
Facility City State ZIP Site status
Not listed Huntsville Alabama
Not listed Phoenix Arizona
Not listed Tucson Arizona
Not listed Covina California
Not listed Hemet California
Not listed La Jolla California
Not listed Palm Desert California
Not listed Upland California
Not listed Victorville California
Not listed Whittier California
Not listed Clearwater Florida
Not listed DeBary Florida
Not listed Jacksonville Florida
Not listed Miami Florida
Not listed Miami Lakes Florida
Not listed New Port Richey Florida
Not listed Orlando Florida
Not listed Plantation Florida
Not listed Kansas City Kansas
Not listed Wichita Kansas
Not listed Elizabethtown Kentucky
Not listed Lexington Kentucky
Not listed Cumberland Maryland
Not listed Hagerstown Maryland
Not listed Wheaton Maryland
Not listed Detroit Michigan
Not listed Saint Clair Shores Michigan
Not listed Eagan Minnesota
Not listed Hattiesburg Mississippi
Not listed Tupelo Mississippi
Not listed St Louis Missouri
Not listed Toms River New Jersey
Not listed Albuquerque New Mexico
Not listed Salisbury North Carolina
Not listed Bethlehem Pennsylvania
Not listed Duncansville Pennsylvania
Not listed Philadelphia Pennsylvania
Not listed Wyomissing Pennsylvania
Not listed Charleston South Carolina
Not listed Columbia South Carolina
Not listed Orangeburg South Carolina
Not listed Memphis Tennessee
Not listed Beaumont Texas
Not listed Corpus Christi Texas
Not listed Dallas Texas
Not listed Mesquite Texas
Not listed San Antonio Texas
Not listed Webster Texas

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 182 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02889796, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jun 8, 2021 · Synced Sep 3, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02889796 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →